The expression of autophagy-related LC3B was analyzed using immunostaining, Western blotting and quantitative real-time polymerase chain reaction (RT-PCR). Compared with non-cirrhotic livers, patients with cirrhotic livers had increased LC3B mRNA and protein levels. Additionally, elevated autophagic activity assessed
via the colocalization of LC3B with lysosome-associated membrane protein-1 (LAMP-1) was NVP-LDE225 molecular weight observed in the cirrhotic livers. Furthermore, using double immunostaining, we found that autophagy was increased in the cytokeratin 19 (CK19)-labeled ductular reactions, and we identified a significantly positive correlation between LC3B and CK19 expression levels. Conclusion: autophagy is upregulated in human cirrhotic livers, correlating with the degree of ductular reaction and fibrosis severity. Therefore, it is reasonable that targeting autophagy
may have therapeutic value for patients with cirrhosis of the liver. Disclosures: The following people have nothing to disclose: Tzu-Min Hung, Po-Huang Carfilzomib mw Lee Introduction. The performance of non-invasive tests of liver fibrosis is evaluated in publications and institutions by AUROC with an obligatory binary target: significant fibrosis or cirrhosis. However, this appears problematic since i) the fibrosis stage is unknown before performing a non-invasive test, and thus the test the best-adapted to the patient’s condition is unknown, and ii) in
clinical practice, clinicians use fibrosis stage selleck chemicals llc classifications reflecting pathological staging. However, these classifications have never been comprehensively evaluated. Our aim was thus to evaluate the diagnostic characteristics of classifications used in clinical practice. Methods. 679 patients with chronic hepatitis C were included in the study and had the following examinations: liver biopsy (Metavir, morphometry), Fibrotest (FT), FibroMeter (FM), CirrhoMeter (CM), Fibroscan (FS) and Elasto-FM (EFM). For Fibroscan, we used a recent classification (JCG 2014) that offers performance superior to that of diagnostic target cut-offs. Classifications were evaluated in terms of accuracy and precision compared to Metavir reference: correlation, concordance, mean difference in F stages between tests and dispersion (number of F stages per class of the test classification). Fibrosis classes were used with their median numerical score (e.g. 1.5 for F1/2). Results. 1/ Accuracy: well classified pts by classification: FT: 38.3%, FM: 84.1%, FS: 88.2%, CM: 83.2%, EFM: 91.7% (p<0.001). AUROC for significant fibrosis (score/classification): FT: 0.782/0.766, FM: 0.821/0.802, FS: 0.802/0.782, CM: 0.799/0.774, EFM: 0.855/0.837. 2/ Precision: difference in F Metavir vs F classification: FT: 1.01 ±0.82, FM: 0.72±0.57, FS: 0.68±0.57, CM: 0.75±0.59, EFM: 0.62±0.57 (p<0.001).